SUDDEN SENSORINEURAL HEARING LOSS (SSNHL): MULTICENTER TREATMENT TRIAL

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 通过在突发性感音神经性听力损失（SSNHL）发作后14天内就诊的受试者中进行随机前瞻性临床试验，比较口服泼尼松与鼓室内注射甲泼尼龙作为SSNHL主要治疗方法的疗效。 通过记录每例研究受试者经历的主要和次要不良事件和疼痛，比较两个治疗组中副作用和/或不良事件的相对风险。确定重度至极重度SSNHL受试者在SSNHL发作后2周内接受主要治疗时听力恢复至正常或接近正常的比例。描述在6个月随访期间接受治疗的SSNHL的自然史。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compare the efficacy of oral prednisone vs intratympanic methylprednisolone as primary treatment of sudden sensorineural hearing loss (SSNHL) by conducting a randomized prospective clinical trial in subjects presenting within 14 days of SSNHL onset. Compare the relative risk of side effects and/or adverse events in the two treatment groups by documenting the major and minor adverse events and pain experienced by each study subject. Determine the proportion of severe-to-profound SSNHL subjects who achieve recovery to normal or near normal hearing when treated primarily within two weeks of SSNHL onset. Describe the natural history of treated SSNHL during a six month follow up interval.